Sct-I10A
Squamous-cell Non-Small-cell Lung Cancer
Sinocelltech Ltd.Phase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
55 Active assets in the Squamous-cell Non-Small-cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Gruppo Oncologico Italiano di Ricerca Clinica | Phase 3 | BBB |
Serplulimab Shanghai Henlius Biotech | Phase 3 | BB |
Pembrolizumab Shanghai Henlius Biotech | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Gruppo Oncologico Italiano di Ricerca Clinica | Phase 3 | BB |
Docetaxel Shanghai Henlius Biotech | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →